✦ LIBER ✦

Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age

✍ Scribed by Vigil, Carlos E.; Tan, Wei; Deeb, George; Sait, Sheila N.; Block, Annemarie W.; Starostik, Petr; Griffiths, Elizabeth A.; Thompson, James E.; Greene, Jessica D.; Ford, Laurie A.; Wang, Eunice S.; Wetzler, Meir

Book ID: 123227296
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 507 KB
Volume: 37
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.07.036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of tipifarnib combined w

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over

✍ Brandwein, J M; Leber, B F; Howson-Jan, K; Schimmer, A D; Schuh, A C; Gupta, V; 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 100 KB

Bortezomib Added to Daunorubicin and Cyt

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

✍ Attar, E. C.; Johnson, J. L.; Amrein, P. C.; Lozanski, G.; Wadleigh, M.; DeAngel 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 230 KB